Enzo Veltri
A5022553664- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Colorectal Cancer Treatments and Studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Inflammatory Biomarkers in Disease Prognosis
- Economic and Financial Impacts of Cancer
- Immune cells in cancer
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Renal Transplantation Outcomes and Treatments
- Cancer therapeutics and mechanisms
- Diabetes and associated disorders
- Medication Adherence and Compliance
- Ferroptosis and cancer prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Peptidase Inhibition and Analysis
Ospedale Santa Maria Goretti
2001-2023
ASL Roma
2014-2020
University of L'Aquila
2019
Tumour Institute of Tuscany
2003
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
1996-1998
Associazione Italiana Di Oncologia Medica
1996
Medico
1996
University of Palermo
1996
<h3>Background</h3> Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. <h3>Patients methods</h3> We conducted retrospective study advanced patients consecutively treated with anti-PD-1/PD-L1 inhibitors, order to compare clinical outcomes according baseline BMI levels as primary analysis. Based on their BMI, were categorized into overweight/obese (≥ 25) non-overweight (< 25). A gender analysis was...
Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We conducted a multicenter observational retrospective study aimed at evaluating the impact of concomitant medications on outcomes, by weighing their associations baseline characteristics (including performance status, burden disease body mass index) underlying causes for prescription. This analysis included consecutive...
Abstract Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials immune checkpoint inhibitors. Materials and Methods Consecutive patients advanced cancer, treated anti-programmed death-1 (PD-1) agents, were evaluated according to the presence pre-existing AIDs. The incidence immune-related adverse events (irAEs) outcomes compared among subgroups. Results A total 751 enrolled; median age was 69 years. Primary tumors as follows:...
Platinum-containing chemotherapy regimens are the standard treatment for patients with advanced non-small-cell lung cancer (NSCLC), although toxicity is common and may significantly affect patient's quality of life (QoL). This trial aimed to assess whether a combination gemcitabine vinorelbine had benefits in terms QoL, without influencing negatively on survival, compared cisplatin-containing regimens.Patients stage IIIB (effusion supraclavicular nodes) or IV documented NSCLC who were...
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
Abstract Background HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, rapid introduction new therapeutics has led to approval pertuzumab combined with trastuzumab and taxane in first-line, emtansine (T-DM1) second-line. Thereby, evidence T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, data from some retrospective reports suggesting lower activity. The purpose present study...
Dihydropyrimidine dehydrogenase (DPD) catabolises ∼85% of the administered dose fluoropyrimidines. Functional DPYD gene variants cause reduced/abrogated DPD activity. analysis may help for defining individual patients' risk fluoropyrimidine-related severe toxicity. The TOSCA Italian randomised trial enrolled colon cancer patients 3 or 6 months either FOLFOX-4 XELOX adjuvant chemotherapy. In an ancillary pharmacogenetic study, 10 (*2A rs3918290 G>A, *13 rs55886062 T>G, rs67376798 A>T, *4...
Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes two or more chemotherapy lines for advanced disease.This multicenter observational retrospective study performed order to evaluate activity tolerability of eribulin real-world patient population.133 breast cancer pretreated ≥ 2 metastatic disease were retrospectively enrolled the trial 11 italian centres.A median 5 cycles (range, 1-15) administered. Twenty-eight partial responses...
Abstract In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and lesions is widely recognized, however clinical implications are unknown. Our study address question if relevant differences exist subjects who preserve HER2 those gain positivity when relapsed. Data patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world setting at 45 Italian centers were...
We investigated 17 polymorphisms in 11 genes (TS, MTHFR, ERCC1, XRCC1, XRCC3, XPD, GSTT1, GSTP1, GSTM1, ABCC1, ABCC2) for their association with the toxicity of fluoropyrimidines and oxaliplatin colorectal cancer patients enrolled a prospective randomized trial adjuvant chemotherapy. The TOSCA Italian was conducted high-risk stage II–III treated 6 or 3 months either FOLFOX-4 XELOX In concomitant ancillary pharmacogenetic study, primary endpoint grade 3–4 CTCAE events (grade 2–4...
We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test.Median follow-up, length pertuzumab, trastuzumab maintenance 21, 4 15 months, respectively. The response rate was 77.3%, clinical benefit 93.6%. Median progression-free survival (mPFS) 21 median overall (mOS) not...
Body mass index (BMI) is a main indicator of obesity and its association with breast cancer well established. However, little known in the metastatic setting, especially HER2-positive patients. We assessed influence BMI on clinical outcomes patients treated pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ (mBC). was addressed as categorical variable, being classified basis following ranges, that is, 18.5-24.9, 25-29.9, 30.0-34.9, namely, normal weight, overweight, Class I obesity....
Background In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider use of adjuvant capecitabine, based on results randomized CREATE-X study, carried out in Asian and including a small subset tumors. Thus far, evidence Caucasian limited, no real-world data are available. Methods We multicenter, observational involving 44 oncologic centres. Triple disease,...
Abstract Data from 423 human epidermal growth factor receptor 2‐negative (HER2−), hormone receptor‐positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian centers analyzed for treatment outcomes. Overall, 158 in first line 265 second/later lines. We observed 19 complete responses 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) clinical benefit 52.7% CI,...
Abstract Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is multicentre, randomized, non-inferiority, phase III study conducted high-risk stage II/stage CC patients treated with 6 vs 3 months of FOLFOX-4 or XELOX adjuvant chemotherapy. During this post-hoc analysis, 218 women 294 men were genotyped 17 polymorphisms: TYMS (rs34743033, rs2853542, rs11280056), MTHFR (rs1801133,...
A biosimilar medicine is one with proven similarity to a reference biological product for which the patent has expired and whose active ingredient produced or derived from living organism. Recombinant granulocyte colony-stimulating growth factors (G-CSF) are used prophylaxis of febrile neutropenia.In this observational, single-center study, total 48 patients solid tumors were treated new G-CSF (Zarzio(®)) 4-14 days day following end chemotherapy.Between October 2010 July 2011, was...
Background: Many patients with solid tumours or nonmyeloid haematopoietic develop symptomatic anaemia, which has a major impact on quality of life (QoL). The efficacy erythropoiesis-stimulating agents (ESAs) in improving QoL and reducing blood transfusions been widely demonstrated. Binocrit® (biosimilar epoetin alfa) is an ESA indicated the European Union for treating chemotherapy-induced anaemia. aim this study was to investigate effect haemoglobin (Hb) levels anaemic cancer Italian...
<p>Tumour micron-environment transcriptome analysis.</p>